Assignee
NANTKWEST INC
US·24 granted patents·22 pending applications·144 citations·filing 2014–2021
Top patents by PatentIndex Score
46 records- 0197US11230699B2Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptorsNANTKWEST INC·Filed 2020·Granted Jan 25, 2022·9 cites·27 claims
- 0297US11207350B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2021·Granted Dec 28, 2021·11 cites·11 claims
- 0397US11000550B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2020·Granted May 11, 2021·6 cites·9 claims
- 0496US11077143B2Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cellsNANTKWEST INC·Filed 2019·Granted Aug 3, 2021·16 cites·9 claims
- 0596US10738279B2Modified NK-92 cells for treating cancerNANTKWEST INC·Filed 2016·Granted Aug 11, 2020·16 cites·20 claims
- 0695US10960024B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Mar 30, 2021·17 cites·18 claims
- 0795US10765701B2Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cellsNANTKWEST INC·Filed 2019·Granted Sep 8, 2020·7 cites·25 claims
- 0895US10456420B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2016·Granted Oct 29, 2019·19 cites·11 claims
- 0993US11129850B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Sep 28, 2021·8 cites·4 claims
- 1093US11058723B2Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapiesNANTKWEST INC·Filed 2019·Granted Jul 13, 2021·8 cites·7 claims
- 1193US10736921B2Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancerNANTKWEST INC·Filed 2019·Granted Aug 11, 2020·5 cites·12 claims
- 1292US10774310B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2019·Granted Sep 15, 2020·4 cites·11 claims
- 1391US10517895B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2019·Granted Dec 31, 2019·5 cites·20 claims
- 1491US10258649B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2014·Granted Apr 16, 2019·9 cites·17 claims
- 1588US10801013B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2018·Granted Oct 13, 2020·2 cites·14 claims
- 1686US11753625B2Modified NK-92 haNK003 cells for the clinicNANTKWEST INC·Filed 2020·Granted Sep 12, 2023·1 cites·18 claims
- 1777US10646516B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2018·Granted May 12, 2020·0 cites·18 claims
- 1876US12540170B2Chemokine responsive activated natural killer cells with secondary homing activation for verified targetsNANTKWEST INC·Filed 2018·Granted Feb 3, 2026·1 cites·7 claims
- 1974US11304977B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2019·Granted Apr 19, 2022·0 cites·5 claims
- 2070US11213547B2Tumoricidal and antimicrobial compositions and methodsNANTKWEST INC·Filed 2019·Granted Jan 4, 2022·0 cites·17 claims
- 2170US10772912B2Tumoricidal and antimicrobial compositionNANTKWEST INC·Filed 2019·Granted Sep 15, 2020·0 cites·15 claims
- 2268US12498363B2Combined invasion and cytotoxicity assay using chemokine secreting target cellsNANTKWEST INC·Filed 2019·Granted Dec 16, 2025·0 cites·13 claims
- 2362US2021008107A1CIML NK cells and Methods ThereforNANTKWEST INC·Filed 2019·Application pending·0 cites
- 2461US11351196B2Generating CIK NKT cells from cord bloodNANTKWEST INC·Filed 2021·Granted Jun 7, 2022·0 cites·25 claims
- 2558US2021008112A1CIML NK cells and Methods ThereforNANTKWEST INC·Filed 2020·Application pending·0 cites
- 2656US2022133789A1Generating cik nkt cells from cord bloodNANTKWEST INC·Filed 2019·Application pending·0 cites
- 2754US2020155599A1Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatmentNANTKWEST INC·Filed 2018·Application pending·0 cites
- 2854US2021169931A1Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selectionNANTKWEST INC·Filed 2020·Application pending·0 cites
- 2953US2021106619A1NK-92 Bone and Brain targetingNANTKWEST INC·Filed 2020·Application pending·0 cites
- 3052US2022017594A1Il-2 dependent nk-92 cells with stable fc receptor expressionNANTKWEST INC·Filed 2019·Application pending·0 cites
- 3152US2021040175A1Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validationNANTKWEST INC·Filed 2020·Application pending·0 cites
- 3251US2020096511A1Sample destruction validation system and methodsNANTKWEST INC·Filed 2019·Application pending·0 cites
- 3349US2020306302A1Treating and inhibiting leukemia with nk-92 cellsNANTKWEST INC·Filed 2018·Application pending·0 cites
- 3448US2021198628A1Basal media for growing nk-92 cellsNANTKWEST INC·Filed 2019·Application pending·0 cites
- 3548US2020171087A1Methods for treating merkel cell carcinoma (mcc) using nk-92 cellsNANTKWEST INC·Filed 2018·Application pending·0 cites
- 3647US2021187024A1NK-92 Cells to Stimulate Anti-Cancer VaccineNANTKWEST INC·Filed 2018·Application pending·0 cites
- 3746US12503680B2Methods and systems for cell bed formation during bioprocessingNANTKWEST INC·Filed 2019·Granted Dec 23, 2025·0 cites·6 claims
- 3843US2022265716A1Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysisNANTKWEST INC·Filed 2020·Application pending·0 cites
- 3942US2020121720A1Nk-92 cells and il-15 agonist combination therapyNANTKWEST INC·Filed 2018·Application pending·0 cites
- 4039US2019233797A1Hla class i-deficient nk-92 cells with decreased immunogenicityNANTKWEST INC·Filed 2017·Application pending·0 cites
- 4139US2021267190A1CryopreservationNANTKWEST INC·Filed 2019·Application pending·0 cites
- 4239US2020123503A1Genetically modified nk-92 cells with decreased cd96/tigit expressionNANTKWEST INC·Filed 2018·Application pending·0 cites
- 4337US2021040451A1Use of 5% human albumin in wash and harvest mediaNANTKWEST INC·Filed 2019·Application pending·0 cites
- 4437US2017182292A1Treating solid tumours with nk-92 cells applied by microcatheterNANTKWEST INC·Filed 2015·Application pending·0 cites
- 4537US2017304364A1Nk-92 cells in combination therapy with cancer drugsNANTKWEST INC·Filed 2016·Application pending·0 cites
- 4635US2021363484A1Optimization of nk-92 cell growth using poloxamerNANTKWEST INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →